111, Inc. (NASDAQ:YI - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 6,100 shares, a decrease of 74.3% from the January 31st total of 23,700 shares. Based on an average trading volume of 34,900 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the shares of the stock are sold short.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. FIL Ltd acquired a new stake in 111 in the 4th quarter valued at about $450,000. Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in shares of 111 in the 4th quarter valued at $245,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after purchasing an additional 305,339 shares in the last quarter. Institutional investors and hedge funds own 21.32% of the company's stock.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 111 in a report on Wednesday, February 19th.
Get Our Latest Report on YI
111 Stock Down 3.2 %
Shares of 111 stock traded down $0.29 on Monday, hitting $8.59. 7,234 shares of the company were exchanged, compared to its average volume of 20,319. The company has a 50-day moving average price of $6.46 and a 200 day moving average price of $7.30. The stock has a market capitalization of $73.42 million, a price-to-earnings ratio of -2.15 and a beta of 0.41. 111 has a 1-year low of $4.15 and a 1-year high of $15.80.
111 (NASDAQ:YI - Get Free Report) last issued its earnings results on Wednesday, November 27th. The company reported ($0.20) earnings per share (EPS) for the quarter.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
See Also
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
